Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 12, 2002 - Issue 3
Submit an article Journal homepage
99
Views
14
CrossRef citations to date
0
Altmetric
Miscellaneous

Inhibitors of protein-protein interactions

Thomas R Gadek Genentech, Inc., One DNA Way, South San Francisco, CA 94080, USA, Tel.: +1 650 225 3361; Fax: +1 350 225 2061, E-mail: [email protected]
&
Denise A Ockey SUGEN, Inc., 230 East Grand Avenue, South San Francisco, CA 94080, USA
Pages 393-400 | Published online: 25 Feb 2005

Bibliography

  • DARNELL JE, HARVEY, HF, D: Molecular Cell Biology. Scientific American Books, W. H. Freeman and Company, NY, USA (1986) 1192.
  • COCHRAN AG: Antagonists of protein-protein interactions. Chem. Biol. (2000) 7:R85–R94.
  • HENIG L, CORNISH WC: ha vivo protein-protein interaction assays: Beyond proteins. Angew. Chem. Int. Ed. (2001) 40:871–875.
  • VON ANGERER E: New inhibitors of tubulin polymerisation. Expert Opin. Titer. Patents (1999) 9(8):1069–1081.
  • JORDAN A, HADFIELD JA, NJ, MCGOWN AT: Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med. Res. Rev (1998) 18(4):259–296.
  • RAI SS, WOLFF J: Localization of the-binding site on 3-tubulin. J. Biol. Chem. (1996) 271(25):14707–14711.
  • HAMEL E: Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmacol The,: (1992) 55(1):31–51.
  • UCKUN FM: SUDBECK EA, MAO C et al. Structure-based design of novel anticancer agents. Carr. Cancer Drug Targets (2001) 1(1):59–71.
  • REILLY TM, MOUSA SA, RACANELLI AL: New antiplatelet drugs. Emerging Drugs (1999) 4:197–208
  • VAISMAN D, FERGUSON JJ: Therapeutic of GPreceptor antagonistsin acute myocardial infarction. Expert Opin. Investig. Drugs (2001) 10(11):1965–1976.
  • PALANKI MSS, MANNING AM: Interleukin-2 inhibitors in autoimmune disease. Expert Opin. Ther. Patents (1999) 9(1):27–39.
  • TILLEY JVV, CHEN L, FRY, DC et al: Identification of a Small Molecule Inhibitor the IL-2/IL-2Ra Receptor Interaction Which Binds to IL-2. I Am. Chem. Soc. (1997) 119(32):7589–7590.
  • LIU G: Small molecule antagonists of the LFA-1/ICAM-1 interaction as potential therapeutic agents. Expert Opin. Ther. Patents (2001) 11(9):1383–1393.
  • KALLENJ, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD1 la I-domain. J. Ma Biol. (1999) 292:1–9.
  • HUTH JR, OLENJNICZAK ET, MENDOZA R et al: NMR and mutagenesis evidence for an I-domain allosteric site that regulates lymphocyte function-associated antigen-1 ligand binding. Proc. Nati Acad. Sci. USA (2000) 97:5231–5236.
  • GADEK TR, MARSTERS Jr. JC, STANLEY M et al.: Identification and characterization of antagonists of the LFA-1/ ICAM-1 protein-protein interaction as novel immunomodulatory agents. 220th ACS National Meeting, Washington DC, USA (2000) MEDI 177.
  • GADEK TR, BURDICK DJ, McDOWELLRS et al: Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science (2002) 295:1086–1089.
  • DUGGAN ME, HUTCHINSON JH: Ligands to the Integrin Receptor ad33. Expert Opin. The]: Patents(2000) 10(9):1367–1383.
  • CONNELL, RD, BEEBE JS: Patent focuson cancer chemotherapeutics. III Angiogenesis agents: October 2000 - March 2001. Expert Opin. The]: Patents (2001) 11(7):1171–1203.
  • HARTMAN GD, DUGGAN ME: aj33 integrin antagonists as inhibitors of bone resorption. Expert Opin. Investig. Drugs (2000) 9(6):1281–1291.
  • HORTON MA, RODAN GA: Integrins as therapeutic targets in bone disease. In: Adhesion Receptors as Therapeutic Targets. Horton MA (Ed.), CRC Press, Boca Raton, FL, USA (1996):223–245.
  • BROOKS PC, CLARK RAF, CHERESH DA: Requirement of vascular integrin aj33 for angiogenesis. Science (1994) 264:569–571.
  • CHICO, TJA, CHAMBERLAIN J, GUNN J et al.: Effect of selective or combined inhibition of integrins allbl33 and aj33 on thrombosis and neointima after oversized porcine coronary angioplasty. Circulation (2001) 103:1135–1141.
  • CARRON CP, MEYER DM, PEGG JA et al.: A peptidomimetic antagonist of the integrin avI33 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. (1998) 58(9):1930–1935.
  • ZIMMERMAN CN: Peptide and peptidomimetic inhibitors of VLA-4. Expert Opin. The]: Patents(1999) 9:129–133.
  • LIN K-C, CASTRO AC: Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curt Opin. Chem. Biol. (1998) 2:453–457.
  • JACKSON DY: a4 Integrin Antagonists. Curt Pharm. Design. (2002). In press.
  • TUBRIDY N, BEHAN PO, CAPILDEO R et al.: The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 53: 466–472.
  • PLEISS MA, THORSETT ED, T: Discovery of a novel binding epitope for the a4 integrin based on sequence homology between VCAM-1 and third heavy chain complementary-determining region of anti-a4 antibodies. Abstr. Pap. Am. Chem. Soc. (2000) 220th: MEDI–132.
  • MULLER G: Peptidomimetic 5H2 domain antagonists for targeting signal transduction. Top. Curt Chem. (2001) 211:17–59.
  • SHAKESPEARE WC: 5H2 domain inhibition: a problem solved? Can: Opin. Chem. Biol. (2001) 5(4):409–415.
  • No authors listed. New inhibitors of 5H2-mediated processes. Expert Opin. Titer: Patents. (1998) 8(3):333–335.
  • SMITHGALL TE: 5H2 and 5H3 domains: potential targets for anti-cancer drug design. Pharmacol Toxicol Methods. (1995) 34(3):125–132.
  • MCBRIDE CB, MCPHAIL LT, STEEVES JD: Emerging therapeutic targets in caspase-dependent disease. Emerging The]: Targets (1999) 3:391–411.
  • DEGTEREV A, LUGOVSKOY A, CARD ONE M et al.: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-XL. Nat. Cell Biol. (2001) 3(2):173–182.
  • HOLINGER EP, CHITTENDEN T, LUTZ RJ: Bak BH3 peptides antagonize Bc1-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem. (1999) 274(19):13298–13304.
  • TZUNG S-P, KIM KM, BASANEZ G et al.: Antimycin A mimics a cell-death-inducing Bc1-2 homology domain 3. Nat. Cell Biol. (2001) 3(2):183–192.
  • ZUTSHI R, BRICKNER M, J: Inhibiting the assembly of protein-protein interfaces. Curt: Opin. Chem. Biol. (1998) 2:62–66.
  • SHULTZ MD, BOWMAN MJ, HAM Y-W et al: Small-molecule inhibitors of HIV-1 protease dimerization derived from cross-linked interfacial peptides. Angew. Chem. mt. Ed. (2000) 39(15):2710–2713.
  • FAN X, FLENTKE GR, RICH DH: Inhibition of HIV-1 Protease by a Subunit of Didemnaketal A. J. Am. Chem. Soc. (1998) 120(34):8893–8894.

Websites

  • Genentech, Inc. Press Release: Phase III Clinical Trials of Xanelim Humanized Monoclonal Antibody for Moderate-to-Severe Psoriasis Show Preliminary Positive Results. May 24, 2001: http://www.gene.com/gene/news/ press_pipe.html
  • Protein Design Labs, Inc. http://www.pdl.com/wt/ sec.php3?page_nameproducts
  • ICOS, Inc.: Information on the development status of IC747: http://www.icos.com
  • MedImmune, Inc.://www.medimmune.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.